Emergent BioSolutions Inc. (FRA:ER4)
Germany · Delayed Price · Currency is EUR 9.63
+0.02 (0.25%)
At close: Nov 27, 2025
Revenue by Product
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2003 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2003 - 2019 |
Medical Countermeasures Products | 509.80M | Log In | Log In | Log In | Log In | Upgrade |
Medical Countermeasures Products Growth | 14.00% | Log In | Log In | Log In | Log In | Upgrade |
Commercial Products | 398.90M | Log In | Log In | Log In | Log In | Upgrade |
Commercial Products Growth | -19.79% | Log In | Log In | Log In | Log In | Upgrade |
Services | 104.90M | Log In | Log In | Log In | Log In | Upgrade |
Services Growth | 33.63% | Log In | Log In | Log In | Log In | Upgrade |
Reconciling Items | 30.00M | Log In | Log In | Log In | Log In | Upgrade |
Reconciling Items Growth | 14.07% | Log In | Log In | Log In | Log In | Upgrade |
Government - Medical Countermeasures and Commercial Product | - | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing Services | - | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing Services Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Nasal Naloxone Products | - | Log In | Log In | Log In | Log In | Upgrade |
Nasal Naloxone Products Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing - Services | - | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing - Leases | - | Log In | Log In | Log In | Log In | Upgrade |
Anthrax Vaccines | - | Log In | Log In | Log In | Log In | Upgrade |
Anthrax Vaccines Growth | - | Log In | Log In | Log In | Log In | Upgrade |
ACAM2000 | - | Log In | Log In | Log In | Log In | Upgrade |
ACAM2000 Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2003 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2003 - 2019 |
Other | 80.60M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -63.01% | Log In | Log In | Log In | Log In | Upgrade |
United States | 822.60M | Log In | Log In | Log In | Log In | Upgrade |
United States Growth | 35.47% | Log In | Log In | Log In | Log In | Upgrade |
Canada | 140.40M | Log In | Log In | Log In | Log In | Upgrade |
Canada Growth | -37.38% | Log In | Log In | Log In | Log In | Upgrade |
Other | 80.60M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -63.01% | Log In | Log In | Log In | Log In | Upgrade |